{
H. Lundbeck A/S

Companies

}
001122334455554433221100
001122334455554433221100

Lundbeck shares decline after Deutsche Bank downgrades stock to hold

Shares of H. Lundbeck A/S dropped over 6% after Deutsche Bank downgraded the stock to "hold" from "buy," citing concerns about the company's growth trajectory and lowering its price target from DKK 53 to DKK 44. Analyst Manos Mastorakis noted that despite strong performance earlier in 2024, recent developments, including the Capital Markets Day and the acquisition of Longboard Pharmaceuticals, have led to a reassessment of Lundbeck's valuation, with P/E ratios reflecting a significant decline. While some products like Rexulti and Vyepti show promise, the PACAP pipeline is no longer viewed as a major growth driver, prompting a more cautious outlook on the company's future.
Investing.com
Danish Krone H. Lundbeck A/S Deutsche Bank Money Market PP DNK Manos Mastorakis
Business & Industry, Market Report
10:22 02.04.2025

regeneron faces sales uncertainty while madrigal reports strong drug launch results

Regeneron Pharmaceuticals' shares dropped nearly 10% as third-quarter sales of Eylea fell short of expectations, raising concerns about future sales amid competition. In contrast, Madrigal Pharmaceuticals reported strong sales of its MASH drug, Rezdiffra, totaling $62 million, significantly exceeding forecasts. UCB's Alzheimer’s drug trial showed promising secondary results despite missing its main goal, while AbbVie announced a partnership with EvolveImmune Therapeutics to develop cancer therapies.
BioPharma Dive
United States Dollar Regeneron Pharmaceuticals, Inc. H. Lundbeck A/S AbbVie Inc. PTC Therapeutics, Inc. UCB SA USA Alistair Henry David Risinger Joseph Schwartz Brian Abrahams Show more
Finance & Economy, Market Report
11:06 01.11.2024

ubs raises lundbeck target price to 49 dkk maintaining neutral stance

UBS has raised its target price for H Lundbeck A/S to DKK 49, maintaining a neutral stance on the stock. The Denmark-based pharmaceutical company specializes in developing treatments for brain diseases, including Alzheimer's, depression, and Parkinson's, with a diverse product portfolio.
MarketScreener
Danish Krone H. Lundbeck A/S DNK Show more
TradFi, Market Report
09:54 16.10.2024

lundbeck acquires longboard pharmaceuticals for 2.6 billion dollars to enhance brain drug portfolio

Danish drugmaker Lundbeck has agreed to acquire Longboard Pharmaceuticals for $2.6 billion, paying $60 per share, a 54% premium. The deal aims to enhance Lundbeck's portfolio with bexicaserin, a potential treatment for developmental and epileptic encephalopathies, which could generate annual sales of $1.5 billion to $2 billion. The acquisition is expected to close by year-end, positioning Lundbeck for growth as it faces patent expirations on key products.
BioPharma Dive
United States Dollar H. Lundbeck A/S Arena Pharmaceuticals Inc. Longboard Pharmaceuticals, Inc. Pfizer Inc. DNK Charl van Zyl Arena Pharmaceuticals Show more
Finance & Economy, Market Report
14:14 14.10.2024
Trending
Subcategory
Industry Trends Corporate News Startups & Entrepreneurship Supply Chain Management Retail and Consumer Goods Global Trade Developments Private Equity Deals Industry Mergers & Acquisitions Government Economic Policies CEO Changes Workplace Trends Stock Market Updates Corporate Social Responsibility Emerging Startups Funding Rounds & Investments Consumer Protection Regulations Energy Sector Developments Fintech Startups AI Innovations Global Trade Policies
Countries:
USA CHN IND ARE JPN SAU SGP GBR EGY IDN KOR TWN QAT DEU VNM MYS NGA HKG BRA MEX
Companies:
Apple Inc. NVIDIA Corporation Google Inc. Amazon.com, Inc. Tesla, Inc. JD.com, Inc. Toyota Motor Corp Honda Motor Co., Ltd. Microsoft Corporation The Goldman Sachs Group, Inc. Samsung Securities Co.,Ltd. Meituan XIAOMI-W Tesmec S.p.A. TENCENT Emirates NBD Bank PJSC Boeing Co Foxconn Technology Co., Ltd. HP Inc. KiloEx USD
Currencies:
United States Dollar Chinese Yuan Indian Rupee Euro Japanese Yen British Pound Sterling Offshore Chinese Yuan Indonesian Rupiah Vietnamese Đồng South Korean Won Nigerian Naira Nicaraguan Córdoba New Taiwan Dollar Qatari Riyal Mexican Peso Pakistani Rupee Saudi Riyal Malaysian Ringgit Singapore Dollar Macanese Pataca
People:
Donald Trump Tim Cook Mark Zuckerberg Haider Ali Khan Xi Jinping Jensen Huang Piyush Anchliya Stiven Muccioli Tamim bin Hamad Al Thani Pandu Sjahrir Prabowo Subianto Changpeng Zhao Prashant Joshi Amal El Fallah Seghrouchni He Xiaopeng Abdel Fattah El-Sisi Bisrat Degefa Howard Lutnick Han-wei Lu Scott Bessent

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.